Identification of the lymph node metastasis-related automated breast volume scanning features for predicting axillary lymph node tumor burden of invasive breast cancer via a clinical prediction model

Feng Zhao1,2,3†, Changjing Cai2,4†, Menghan Liu3 and Jidong Xiao3* 

1Department of Cardiovascular Surgery, Xiangya Hospital, Central South University, Changsha, China, 2National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, 3Department of Ultrasound, Third Xiangya Hospital, Central South University, Changsha, China, 4Department of Oncology, Xiangya Hospital, Central South University, Changsha, China

Breast cancer has become the malignant tumor with the highest incidence in women. Axillary lymph node dissection (ALND) is an effective method of maintaining regional control; however, it is associated with a significant risk of complications. Meanwhile, whether the patients need ALND or not is according to sentinel lymph node biopsy (SLNB). However, the false-negative results of SLNB had been reported. Automated breast volume scanning (ABVS) is a routine examination in breast cancer. A real-world cohort consisting of 245 breast cancer patients who underwent ABVS examination were enrolled, including 251 tumor lesions. The ABVS manifestations were analyzed with the SLNB results, and the ALND results for selecting the lymph node metastasis were related to ABVS features. Finally, a nomogram was used to construct a breast cancer axillary lymph node tumor burden prediction model. Breast cancer patients with a molecular subtype of luminal B type, a maximum lesion diameter of ≥5 cm, tumor invasion of the Cooper’s ligament, and tumor invasion of the nipple had heavy lymph node tumor burden. Molecular classification, tumor size, and Cooper’s ligament status were used to construct a clinical prediction model of axillary lymph node tumor burden. The consistency indexes (or AUC) of the training cohort and the validation cohort were 0.743 and 0.711, respectively, which was close to SLNB (0.768). The best cutoff value of the ABVS nomogram was 81.146 points. After combination with ABVS features and SLNB, the AUC of the prediction model was 0.889, and the best cutoff value was 178.965 points. The calibration curve showed that the constructed nomogram clinical prediction model and the real results were highly consistent. The clinical prediction model constructed using molecular classification, tumor size, and Cooper’s ligament status can effectively predict
the probability of heavy axillary lymph node tumor burden, which can be a significant supplement to the SLNB. Therefore, this model may be used for individual decision-making in the diagnosis and treatments of breast cancer.

KEYWORDS
ABVS, ultrasound, breast cancer, ALND, SLNB

Introduction

At present, breast cancer has become the malignant tumor with the highest incidence in women (1), and the onset of breast cancer has been occurring at younger and younger ages. Axillary lymph node dissection (ALND) is an effective method of maintaining regional control; however, it is associated with a significant risk of complications such as lymphedema, numbness, axillary web syndrome, and decreased upper-extremity range of motion (2, 3). The Z0011 trial conducted by the American College of Surgeons Oncology Group (ACOSOG) showed that if the postoperative treatments are standardized, patients with one or two positive lymph nodes in sentinel lymph node biopsy (SLNB) do not need an ALND (2, 4). Only breast cancer patients with three or more metastatic axillary lymph nodes are required to undergo surgical dissection. Therefore, Li et al. (5) proposed the concept of lymph node tumor burden, which defines fewer than three axillary lymph node metastases as a mild lymph node tumor burden, and three or more as a heavy lymph node tumor burden. The results of the ACOSOG Z0011 trial have changed the treatment of breast cancer. Studies have shown that the overall proportion of patients who met the Z0011 standard for parallel surgery has dropped from 34.0% to 22.7%, and there is a declining trend year by year (4, 6). Currently, lymphatic metastasis is mainly determined by SLNB; however, false-negative results (9.8%) had been reported (7).

Automated breast volume scanning (ABVS) is an emerging technology of breast ultrasound examination that can obtain images of multiple planes, including cross section, sagittal plane, and coronal plane. In addition, it can observe the lesions in real time, dynamically, continuously, and multi-sectionally, providing more information on the imaging manifestations of the lesions and the surrounding tissues of the lesions (8). Ultrasound is a common method for screening breast diseases, and the ultrasound manifestations of different molecular subtypes of breast cancer are slightly different, especially in ABVS technology (9). In addition, studies have shown that different molecular subtypes of breast cancer have different biological behaviors (10), different prognosis (11), and different distant metastasis statuses, i.e., the axillary lymph node metastasis status is different (12, 13). Therefore, if the relationship between the ABVS manifestations and the molecular subtype of the primary breast cancer lesion with the status of axillary lymph node metastasis can be ascertained, more imaging evidence for assessing the status of the lymph node metastasis can be provided.

Therefore, we initiated a real-world analysis. First, we performed some analyses of the clinical features, ABVS features, and lymph node tumor burden. Then, the features related to the lymph node tumor burden were selected. Finally, a clinical prediction model of lymph node tumor burden was developed. Our work indicated there are strong links between ABVS features and lymph node tumor burden, and the clinical prediction model can be the significant supplement to the SLNB, and this model may be used for individual decision-making.

Materials and methods

Xiangya real-world cohort patients

The patients who underwent ABVS examination in the Department of Ultrasound of Third Xiangya Hospital of Central South University and were confirmed to have breast cancer by postoperative pathological examination from June 2017 to June 2019 were included. There was a total of 245 patients and 251 tumor lesions. The patients were screened according to the inclusion criteria and exclusion criteria. This study was approved by the ethics committee of Third Xiangya Hospital of Central South University.

The inclusion criteria were (1) preoperative ABVS examination in our hospital and postoperative pathological confirmation of breast cancer and (2) complete clinical and pathological data. The exclusion criteria were as follows (1): not newly diagnosed with breast cancer (2); the patients without the ABVS results before neoadjuvant chemotherapy (chemotherapy before surgery); and (3) the clinical data and pathological results were incomplete (4); the patients with poor-quality ABVS images: the scanning operation is not standardized—the breast gland scanning is incomplete, the scanning depth is too large or too small, and the gain is too large or too small, the gray-scale setting is based on fat tissue, and the fat lobules are medium gray, not black—and artifacts: the probe does not fit well with the patient’s
skin, causing artifacts, and the glands are not flattened; the posterior echo attenuation of the image generated by the wrinkles in the nipple and areola area, and coupling agent solidification, small bubbles.

The patients with the relative contraindication for ABVS examination were described as the following; there is no absolute contraindication, but it is recommended to use it with caution or check it after full communication with the patient in the following cases—in the middle and late trimesters of pregnancy, lactation, acute mastitis, great pain of breast, breast prosthesis, and breast skin ulceration.

**ABVS examination**

A Siemens ACUSON S2000 ABVS acquisition system was used for image acquisition for all of the selected subjects; the probe model was 14L5BV, the frequency was 5.0–12.0 MHz, and the maximum scan volume was 154 mm × 168 mm × 60 mm. The patient was in a supine position with both hands raised over the head to fully expose the breasts on both sides. The mechanical arm was adjusted so that the probe could exert proper pressure to contact the breast without causing patient discomfort. The settings of the instrument were preset according to the size of the patient’s breasts. Then the machine scanned the median, lateral, and medial positions of the breast sequentially and, when necessary, scanned other planes. After the scan was completed, the position of the nipple was marked, and the images were uploaded to the image processing workstation for image reconstruction. If a mass was identified, the image features of the mass on the ABVS images were extracted, including tumor size (≤2 cm/2–5 cm/≥5 cm). Clinically, the TNM staging method is used for clinical staging of breast cancer, where T represents the size of the tumor, N represents lymph node invasion, and M is used for clinical staging of breast cancer, where T represents the diameter of the lesion is 2 cm/2–5 cm/≥5 cm, which is the current T staging standard and also the size grouping method used in this study. The use of tumor size to determine the degree of breast cancer malignancy and the range of invasiveness has been recognized. Shape (regular/irregular), margin (circumscribed/angular/microlobulated/spiculated), orientation (parallel/non-parallel), echo pattern (hypoechoic/mixed solid echo), posterior acoustic pattern (enhanced/shadow/no change), retraction phenomenon (present/absent), acoustic halo (present/absent), microcalcification (present/absent: microcalcifications were observed as echogenic dots within the mass or as a dilated duct on the ABVS images (14)), invasion of Cooper’s ligament (present/absent: Cooper’s ligaments were considered shortened, thickened, pulled, and straightened, when there were hyperechogenic lines near the mass, radiating toward the skin and thus differing from other parts of normal breast tissue. Cooper’s ligaments were considered normal if this feature was absent (15)), and BI-RADS (breast imaging reporting and data system) classification (class 3/4a/4b/4c/5) were determined. Two doctors independently evaluated all of the acoustic image characteristics with intermediate or higher titles. Disagreements were resolved by a third doctor with a senior title. According to the study of Eda et al., for mass lesions, malignant features include irregular margin, irregular shape, non-parallel growth, peripheral hyperechoic halo, posterior acoustic pattern attenuation, and microcalcification. In addition, one malignant sign is categorized as class 4a, two malignant signs as class 4b, three as class 4c, and more than three as class 5 (16).

**Determination of surrogate molecular subtypes**

According to the St. Gallen consensus and ASCO/CAP (American Society of Clinical Oncology/College of American Pathologists) guidelines, if the stained cells exceed 1% of the total number of cells, the patient is considered PR- (progesterone receptor) and ER- (estrogen receptor) positive; if the number of stained cells is less than 1% of the total number of cells, the patient is considered PR- and ER-negative (17, 18). The Ki-67 proliferation index is determined by the percentage of the number of stained cells in the total number of tumor cells, with 20% as the cutoff value (<20% is considered low proliferation, and ≥20% is considered high proliferation (19, 20)). The HER2 (human epidermal growth factor receptor 2) gene was detected using immunohistochemistry (IHC), and the IHC results were scored as 0, 1+, 2+, and 3+ according to the standards. The 2+ specimens were further examined using fluorescence in situ hybridization (FISH), and the result was used as a basis for further judgment of the amplification of the HER2 gene. HER2-positive cases included IHC 3+ and FISH-positive individuals of IHC 2+ cases, and HER2-negative cases included IHC 0, 1+, and FISH-negative individuals of IHC 2+ cases (21). Surrogate molecular subtypes were as follows (1): luminal A: ER or PR positive, and Ki-67 of less than 20% (2); luminal B: with ER or PR positive, and Ki-67 of 20% or greater (3); HER2: ER negative, PR negative, and HER2 positive; and (4) triple negative: ER negative, PR negative, and HER2 negative.

**Grouping criteria for axillary lymph node tumor burden**

According to the ACOSOG Z0011 trial results, if follow-up tumor surgery and postoperative comprehensive treatment are standardized, patients with two or fewer positive SLNB do not need to undergo ALND (22). Therefore, sentinel/axillary lymph node metastasis ≥3 is defined as heavy lymph node tumor...
burden, and sentinel/axillary lymph node metastasis <3 is defined as mild lymph node tumor burden (5).

Statistics

Using R software (RStudio 1.2) and SPSS 25.0 software, the relationship between the ABVS manifestations of different molecular subtypes of breast cancer and lymph node tumor burden was explored through logistic univariate and multivariate regression risk factor analyses. Using SPSS 25.0 software, the chi-square test or Fisher’s exact test was performed to analyze the difference between the mild axillary lymph node tumor burden group and the heavy axillary lymph node tumor burden group. (1. For all theoretical numbers T ≥5 and total sample size n ≥ 40, the Pearson chi-square test was used; 2. If theoretical number T < 5 but ≥ 1, and n ≥ 40, a continuity correction chi-square test was performed; 3. If the theoretical number T <1 or n <40, a Fisher’s test was used.) Finally, based on the logistic regression analysis results, R software was used to construct a nomogram model for breast cancer axillary lymph node tumor burden prediction. MedCalc software (18.2) was used to graph the ROC curve of axillary lymph node tumor burden detected using SLNB and calculate the area under the curve.

Results

Clinical characteristics and pathological data of the study subjects

According to the inclusion and exclusion criteria, a total of 245 eligible patients were screened, and a total of 251 lesions were included in the statistical analysis (Table S1).

Relationship between ABVS manifestations of different molecular subtypes of breast lesions and different levels of axillary lymph node tumor burden

Differences of lymph node tumor burden of luminal A-type breast cancer regarding different ABVS manifestations

In 44 cases of luminal A-type lesions, the lymph node tumor burden was not significantly different with respect to tumor size, shape, margin, orientation, echo pattern, posterior acoustic pattern, retraction phenomenon, and microcalcification were not significantly different between the mild lymph node tumor burden group and the heavy lymph node tumor burden group (P> 0.05) However, the tumor size in the heavy lymph node burden group was larger than in the mild lymph node tumor burden group with statistical significance (χ² = 7.594, P = 0.022). The incidence of acoustic halo in the heavy lymph node tumor burden group was higher than in the mild lymph node tumor burden group with statistical significance (χ² = 5.753, P = 0.016). The Cooper’s ligament invasion proportion in the heavy lymph node tumor burden group was higher than in the mild lymph node tumor burden group with statistical significance (χ² = 11.992, P = 0.001).

We did not detect a significant difference in the sentinel lymph node tumor burden in the analysis of different molecular subtypes. However, in the analysis of axillary lymph node tumor burden, we found that in the luminal A type, HER-2 overexpression type, and triple-negative breast cancer, the proportion of patients with a mild lymph node tumor burden was significantly higher than that of patients with a heavy lymph node tumor burden. In contrast, in luminal B breast cancer, the proportion of patients with heavy lymph node tumor burden was significantly higher than that of patients with mild lymph node tumor burden (72.549% vs. 57.480%, χ² = 8.050, P = 0.046). Our results suggest that molecular classification is an important factor affecting the axillary lymph node tumor burden. Therefore, we further analyzed the subgroups of different molecular subtypes (Table 1).

Differences of lymph node tumor burden of luminal B-type breast cancer regarding different ABVS manifestations

A total of 138 cases of luminal B-type lesions were included. Among the 73 lesions that performed ALND, the lymph node tumor burden was not significantly different with respect to tumor size, shape, margin, orientation, echo pattern, posterior acoustic pattern, retraction phenomenon, microcalcification, invasion of the Cooper’s ligament, and BI-RADS classification (P > 0.05). The incidence of acoustic halo in the heavy lymph node tumor burden group was higher than in the mild lymph node tumor burden group with statistical significance (χ² = 8.734, P = 0.003) (Table 2).
| ABVS features and molecular subtype | Sentinel lymph node tumor burden | Axillary lymph node tumor burden |
|------------------------------------|---------------------------------|---------------------------------|
|                                    | Mild | Heavy | P | Mild | Heavy | P |
| **Tumor size**                     |      |       |  |      |       |  |
| ≥5 cm                              | 8 (5.970%) | 2 (20.000%) | 0.155 | 6 (4.724%) | 8 (15.686%) | 0.022 |
| 2-5 cm                             | 74 (55.224%) | 6 (60.000%) |    | 71 (55.906%) | 30 (58.824%) |   |
| ≤2 cm                              | 52 (38.806%) | 2 (20.000%) |    | 50 (39.370%) | 13 (25.490%) |   |
| **Orientation**                    |      |       |  |      |       |  |
| Not parallel                       | 45 (33.592%) | 2 (20.000%) | 0.499 | 48 (37.795%) | 17 (33.333%) | 0.699 |
| Parallel                           | 89 (66.418%) | 8 (80.000%) |    | 79 (62.205%) | 34 (66.667%) |   |
| **Shape**                          |      |       |  |      |       |  |
| Regular                            | 17 (12.687%) | 0 (0.000%) | 0.609 | 12 (9.449%) | 3 (5.882%) | 0.560 |
| Irregular                          | 117 (87.313%) | 10 (100.000%) |   | 115 (90.551%) | 48 (94.118%) |   |
| **Echo pattern**                   |      |       |  |      |       |  |
| Hypoechoic                         | 119 (88.806%) | 10 (100.000%) | 0.600 | 118 (92.913%) | 49 (96.078%) | 0.731 |
| Mixed solid echo                   | 15 (11.194%) | 0 (0.000%) |  | 9 (7.087%) | 2 (3.922%) |   |
| **Margin**                         |      |       |  |      |       |  |
| Circumscribed                      | 10 (7.462%) | 0 (0.000%) | 0.116 | 3 (2.362%) | 0 (0.000%) | 0.085 |
| Angular                            | 51 (38.060%) | 4 (40.000%) | 46 (36.220%) | 15 (29.412%) |   |
| Microlobulated                     | 18 (13.433%) | 0 (0.000%) | 20 (15.748%) | 3 (65.882%) |   |
| Spiculated                         | 55 (41.045%) | 6 (60.000%) | 58 (45.669%) | 33 (64.706%) |   |
| **Posterior acoustic pattern**     |      |       |  |      |       |  |
| Enhancement                        | 22 (16.418%) | 1 (10.000%) | 1.000 | 21 (16.535%) | 5 (9.804%) | 0.103 |
| Shadow                             | 22 (16.418%) | 2 (20.000%) | 22 (17.323%) | 16 (31.373%) |   |
| No change                          | 90 (67.164%) | 7 (70.000%) | 84 (66.142%) | 30 (58.824%) |   |
| **Microcalcifications**            |      |       |  |      |       |  |
| Present                            | 52 (38.806%) | 3 (30.000%) | 0.742 | 59 (46.457%) | 18 (35.294%) | 0.233 |
| Absent                             | 82 (61.194%) | 7 (70.000%) | 68 (53.543%) | 33 (64.706%) |   |
| **Acoustic halo**                  |      |       |  |      |       |  |
| Present                            | 28 (20.896%) | 2 (20.000%) | 1.000 | 22 (17.323%) | 18 (35.294%) | 0.016 |
| Absent                             | 106 (79.104%) | 8 (80.000%) | 105 (82.677%) | 33 (64.706%) |   |
| **Retraction phenomenon**          |      |       |  |      |       |  |
| Present                            | 17 (12.687%) | 1 (10.000%) | 1.000 | 25 (19.685%) | 10 (19.608%) | 1.000 |
| Absent                             | 117 (87.313%) | 9 (90.000%) | 102 (80.315%) | 41 (80.392%) |   |
| **Invasion of Cooper’s ligament**  |      |       |  |      |       |  |
| Yes                                | 29 (21.642%) | 3 (30.000%) | 0.693 | 37 (29.134%) | 29 (56.863%) | 0.001 |
| No                                 | 105 (78.358%) | 7 (70.000%) | 90 (70.866%) | 22 (43.137%) |   |
| **BI-RADS**                        |      |       |  |      |       |  |
| 3                                  | 11 (8.209%) | 0 (0.000%) | 0.882 | 0 (0.000%) | 0 (0.000%) | 0.068 |
| 4a                                 | 25 (18.657%) | 2 (20.000%) | 14 (11.024%) | 5 (9.804%) |   |
| 4b                                 | 44 (32.836%) | 3 (30.000%) | 48 (37.795%) | 10 (19.608%) |   |
| 4c                                 | 18 (13.433%) | 2 (20.000%) | 24 (18.898%) | 10 (19.608%) |   |
| 5                                  | 36 (26.865%) | 3 (30.000%) | 41 (32.283%) | 26 (50.980%) |   |
| **Molecular subtype**              |      |       |  |      |       |  |
| Luminal A                          | 41 (30.597%) | 1 (10.000%) | 0.226 | 26 (14.173%) | 4 (7.843%) | 0.046 |
| Luminal B                          | 60 (44.776%) | 8 (80.000%) | 65 (57.480%) | 37 (72.549%) |   |
| HER-2                              | 17 (12.687%) | 1 (10.000%) | 20 (15.748%) | 4 (7.843%) |   |
| Triple negative                    | 16 (11.940%) | 0 (0.000%) | 16 (12.598%) | 6 (11.765%) |   |
orientation, echo pattern, posterior acoustic pattern, retraction phenomenon, acoustic halo, microcalcification, invasion of the Cooper’s ligament, and BI-RADS classification. The proportion of Cooper’s ligament invasion in the heavy lymph node tumor burden group was higher than in the mild lymph node tumor burden group with statistical significance ($\chi^2 = 7.749, P= 0.005$) (Table 3).

Differences of lymph node tumor burden of HER-2 overexpression type breast cancer regarding different ABVS manifestations

A total of 35 cases of HER-2 overexpression breast lesions were included. Among the 18 lesions that underwent SLNB, the lymph node tumor burden was not significantly different with respect to tumor size, shape, margin, orientation, echo pattern, posterior acoustic pattern, retraction phenomenon, microcalcification, invasion of the Cooper’s ligament, and BI-RADS classification ($P > 0.05$). In the 24 cases of lesions that underwent ALND, the lymph node tumor burden was not significantly different with respect to tumor size, shape, margin, orientation, echo pattern, posterior acoustic pattern, retraction phenomenon, microcalcification, invasion of the Cooper’s ligament, and BI-RADS classification ($P > 0.05$). The proportion of posterior acoustic pattern in the heavy lymph node tumor burden group was higher than in the mild lymph node tumor burden group with statistical significance ($\chi^2 = 6.900, P = 0.032$) (Table 4).

Differences of lymph node tumor burden of triple-negative type breast cancer regarding different ABVS manifestations

A total of 34 cases of triple-negative breast lesions were enrolled, of which 16 cases underwent SLNB and 22 cases underwent ALND. According to the results of SLNB, no patients were with heavy lymph node tumor burden. In the 22 cases of lesions that underwent ALND, the lymph node tumor burden was not significantly different concerning tumor size, shape, margin, orientation, echo pattern, posterior acoustic pattern, retraction phenomenon, acoustic halo, microcalcification, Cooper’s ligament invasion, and BI-RADS classification ($P > 0.05$). The BI-RADS classification of the heavy lymph node tumor burden group was higher than that of the mild lymphoid tumor burden group with statistical significance ($\chi^2 = 13.387, P = 0.004$) (Table 5).

Relationship between breast cancer ABVS manifestations and different levels of axillary lymph node tumor burden

To better explore the relationship between the clinical features of breast cancer and axillary lymph node tumor burden, which can rule out the influence of other factors, including age, molecular subtype, Ki-67, neoadjuvant chemotherapy, menopause, and tumor site, a univariate logistic regression analysis was performed. The results showed that none of the above factors was statistically significant ($P > 0.05$) (Table S2).

ABVS manifestations, tumor size, shape, margin, orientation, echo Pattern, posterior acoustic pattern, retraction phenomenon, acoustic halo, microcalcification, Cooper’s ligament invasion, and BI-RADS classification were included in an univariate logistic regression analysis. The results showed that the maximum lesion diameter of $\geq$ cm significantly influenced the aggravation of sentinel lymph node tumor burden. At the same time, the difference was not statistically significant ($OR = 6.500, 95\% CI 0.701–60.974, P= 0.080$; Table S3). Therefore, indicators with a P-value $<0.05$ can be included in the multivariate logistic regression analysis. However, because none of the univariate logistic regression analysis results of this study was statistically significant, no indicator could be included in multivariate logistic regression analysis in this study.

Relationship between breast cancer ABVS manifestations and clinical features with axillary lymph node tumor burden

To better explore the relationship between the clinical features of breast cancer and axillary lymph node tumor burden, which can rule out the influence of other factors, including age, molecular subtype, Ki-67, neoadjuvant chemotherapy, menopause, and tumor site, an univariate logistic regression analysis was performed. Neoadjuvant chemotherapy was a risk factor of heavy axillary lymph node tumor burden ($OR = 4.181, 95\% CI 1.509–12.202, P = 0.006$), and nipple invasion significantly increased the risk of heavy axillary lymph node tumor burden ($OR = 6.793, 95\% CI 1.411–48.598, P = 0.025$) (Table S4).

Studies have shown that different molecular subtypes of breast cancer have different prognoses (11). Neoadjuvant chemotherapy can downgrade the clinical stage of breast cancer patients and has different responses in different molecular subtypes (23), suggesting that it may affect postoperative lymph node tumor burden. Therefore, we included indicators with a P-value $<0.05$ and clinical significance in the multivariate logistic regression analysis. Molecular classification and Ki-67 were included in the multivariate logistic regression analysis together with neoadjuvant chemotherapy and nipple invasion. The results showed that the molecular subtype of the luminal B type ($OR = 7.766, 95\% CI 2.022–43.649, P = 0.008$) was an independent risk factor of heavy axillary lymph node tumor burden; in addition, neoadjuvant chemotherapy ($OR = 6.657, 95\% CI 2.017–24.579, P = 0.003$) was also one of the risk factors. We conducted a literature review and data analysis and found a
false-positive result, which will be discussed in the discussion section (Table 6).

Tumor size, shape, margin, orientation, echo pattern, posterior acoustic pattern, retraction phenomenon, acoustic halo, microcalcification, Cooper’s ligament invasion, and BI-RADS classification were included in univariate logistic regression analysis. The results showed that the maximum lesion diameter of ≥5 cm significantly increased the risk of heavy axillary lymph node tumor burden (OR = 5.128, 95% CI 1.530–18.232, P = 0.009), as well as a lesion with acoustic halo

| ABVS feathers          | Sentinel lymph node tumor burden | Axillary lymph node tumor burden |
|------------------------|---------------------------------|---------------------------------|
|                        | Mild | Heavy | P     | Mild | Heavy | P     |
| Tumor size             |      |       |       |      |       |       |
| ≥5 cm                  | 4 (9.756%) | 1 (100.000%) | 0.119 | 1 (3.846%) | 1 (25.000%) | 0.328 |
| 2-5 cm                 | 19 (46.341%) | 0 (0.000%) |       | 12 (46.154%) | 1 (25.000%) |       |
| ≤2 cm                  | 18 (43.902%) | 0 (0.000%) |       | 13 (50.000%) | 2 (50.000%) |       |
| Orientation            |      |       |       |      |       |       |
| ~                      | 13 (31.707%) | 0 (0.000%) | 1.000 | 8 (30.769%) | 0 (0.000%) | 0.550 |
| Parallel               | 28 (68.293%) | 1 (100.000%) |       | 18 (69.231%) | 4 (100.000%) |       |
| Shape                  |      |       |       |      |       |       |
| Regular                | 4 (9.756%) | 0 (0.000%) | 1.000 | 0 (0.000%) | 0 (0.000%) | 1.000 |
| Irregular              | 37 (90.244%) | 1 (100.000%) |       | 26 (100.000%) | 4 (100.000%) |       |
| Echo pattern           |      |       |       |      |       |       |
| Hypoechoic             | 35 (85.366%) | 1 (100.000%) | 1.000 | 24 (92.308%) | 3 (75.000%) | 0.360 |
| Mixed solid echo       | 6 (14.634%) | 0 (0.000%) |       | 2 (7.692%) | 1 (25.000%) |       |
| Margin                 |      |       |       |      |       |       |
| Circumscribed          | 5 (12.195%) | 0 (0.000%) | 1.000 | 1 (3.846%) | 0 (0.000%) | 0.154 |
| Angular                | 16 (39.024%) | 1 (100.000%) |       | 7 (26.923%) | 2 (50.000%) |       |
| Microlobulated         | 3 (7.317%) | 0 (0.000%) |       | 1 (3.846%) | 1 (25.000%) |       |
| Spiculated             | 17 (41.463%) | 0 (0.000%) |       | 17 (65.385%) | 1 (25.000%) |       |
| Posterior acoustic pattern |    |       |       |      |       |       |
| Enhancement            | 6 (14.634%) | 0 (0.000%) | 1.000 | 2 (7.692%) | 1 (25.000%) | 0.452 |
| Shadow                 | 7 (17.073%) | 0 (0.000%) |       | 5 (19.231%) | 0 (0.000%) |       |
| No change              | 28 (68.293%) | 1 (100.000%) |       | 19 (73.077%) | 3 (75.000%) |       |
| Microcalcifications    |      |       |       |      |       |       |
| Present                | 11 (26.829%) | 0 (0.000%) | 1.000 | 12 (46.154%) | 0 (0.000%) | 0.130 |
| Absent                 | 30 (70.171%) | 1 (100.000%) |       | 14 (53.846%) | 4 (100.000%) |       |
| Acoustic halo          |      |       |       |      |       |       |
| Present                | 6 (14.634%) | 1 (100.000%) | 0.167 | 4 (15.385%) | 4 (100.000%) | 0.003 |
| Absent                 | 35 (85.366%) | 0 (0.000%) |       | 22 (84.615%) | 0 (0.000%) |       |
| Retraction phenomenon  |      |       |       |      |       |       |
| Present                | 4 (9.756%) | 0 (0.000%) | 1.000 | 7 (26.923%) | 1 (25.000%) | 1.000 |
| Absent                 | 37 (90.244%) | 1 (100.000%) |       | 19 (73.077%) | 3 (75.000%) |       |
| Invasion of Cooper’s ligament | |     |       |      |       |       |
| Yes                    | 9 (21.951%) | 0 (0.000%) | 1.000 | 10 (38.462%) | 2 (50.000%) | 1.000 |
| No                     | 32 (78.049%) | 1 (100.000%) |       | 16 (61.538%) | 2 (50.000%) |       |
| BI-RADS                 |      |       |       |      |       |       |
| 3                      | 7 (17.073%) | 0 (0.000%) | 1.000 | 0 (0.000%) | 0 (0.000%) | 0.220 |
| 4a                     | 8 (19.512%) | 0 (0.000%) |       | 0 (0.000%) | 1 (25.000%) |       |
| 4b                     | 12 (29.268%) | 1 (100.000%) |       | 14 (53.846%) | 2 (50.000%) |       |
| 4c                     | 4 (9.756%) | 0 (0.000%) |       | 4 (15.385%) | 0 (0.000%) |       |
| 5                      | 10 (24.390%) | 0 (0.000%) |       | 8 (30.769%) | 1 (25.000%) |       |
The multivariate logistic regression analysis included indicators with a P-value <0.05. To exclude the influence of other factors, the significant factors in the multivariate logistic regression analysis of the relationship between clinical features and axillary lymph node tumor burden were also included in the multivariate logistic regression analysis. The included factors were molecular subtype, neoadjuvant chemotherapy, lesion size, acoustic halo, posterior acoustic pattern, and Cooper’s ligament invasion.

(OR = 2.603, 95% CI 1.242–5.446, P = 0.011) and invasion of the Cooper’s ligament (OR = 3.206, 95% CI 1.645–6.353, P = 0.001) (Table S5).

The multivariate logistic regression analysis included indicators with a P-value <0.05. To exclude the influence of other factors, the significant factors in the multivariate logistic regression analysis of the relationship between clinical features and axillary lymph node tumor burden were also included in the multivariate logistic regression analysis. The included factors were molecular subtype, neoadjuvant chemotherapy, lesion size, acoustic halo, posterior acoustic pattern, and Cooper’s ligament invasion.

| TABLE 3 Differences of lymph node tumor burden of luminal B-type breast cancer regarding different ABVS features. |
|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| **ABVS features** | **Sentinel lymph node tumor burden** | **Axillary lymph node tumor burden** | **Sentinel lymph node tumor burden** | **Axillary lymph node tumor burden** |
| Tumor size | Mild | Heavy | P | Mild | Heavy | P |
| ≥5 cm | 3 (5.000%) | 1 (12.500%) | 0.173 | 3 (4.615%) | 5 (13.514%) | 0.150 |
| 2–5 cm | 34 (56.667%) | 6 (75.000%) | 33 (50.769%) | 21 (56.757%) |
| ≤2 cm | 23 (38.333%) | 1 (12.500%) | 29 (44.615%) | 11 (29.730%) |
| Orientation | | | | |
| Not parallel | 22 (36.667%) | 1 (12.500%) | 0.250 | 29 (44.615%) | 12 (32.432%) | 0.295 |
| Parallel | 38 (63.333%) | 7 (87.500%) | 36 (55.385%) | 25 (67.568%) |
| Shape | | | | |
| Regular | 7 (11.667%) | 0 (0.000%) | 0.587 | 3 (4.615%) | 3 (8.108%) | 0.665 |
| Irregular | 53 (88.333%) | 8 (100.000%) | 62 (95.385%) | 34 (91.892%) |
| Echo pattern | | | | |
| Hypoechoic | 57 (95.000%) | 8 (100.000%) | 1.000 | 63 (96.923%) | 36 (97.297%) | 1.000 |
| Mixed solid echo | 3 (5.000%) | 0 (0.000%) | 2 (3.077%) | 1 (2.703%) |
| Margin | | | | |
| Circumscribed | 4 (6.667%) | 0 (0.000%) | 0.301 | 1 (1.538%) | 0 (0.000%) | 0.133 |
| Angular | 24 (40.000%) | 2 (25.000%) | 24 (36.923%) | 10 (27.027%) |
| Microlobulated | 10 (16.667%) | 0 (0.000%) | 10 (15.385%) | 2 (5.405%) |
| Spiculated | 22 (36.667%) | 6 (75.000%) | 30 (46.154%) | 25 (67.568%) |
| Posterior acoustic pattern | | | | |
| Enhancement | 8 (13.333%) | 0 (0.000%) | 0.723 | 8 (0.123%) | 3 (8.108%) | 0.501 |
| Shadow | 12 (20.000%) | 2 (25.000%) | 14 (21.538%) | 12 (32.432%) |
| No change | 40 (66.667%) | 6 (75.000%) | 43 (66.154%) | 22 (59.459%) |
| Microcalciﬁcations | | | | |
| Present | 33 (55.000%) | 3 (37.500%) | 0.461 | 33 (101.609%) | 18 (48.649%) | 1.000 |
| Absent | 27 (45.000%) | 5 (62.5%) | 32 (49.231%) | 19 (51.351%) |
| Acoustic halo | | | | |
| Present | 17 (28.333%) | 1 (12.500%) | 0.671 | 13 (20.000%) | 13 (35.135%) | 0.104 |
| Absent | 43 (71.667%) | 7 (87.500%) | 52 (80.000%) | 24 (64.865%) |
| Retraction phenomenon | | | | |
| Present | 12 (20.000%) | 1 (12.500%) | 1.000 | 15 (23.076%) | 9 (24.324%) | 1.000 |
| Absent | 48 (80.000%) | 7 (87.500%) | 50 (76.923%) | 28 (75.676%) |
| Invasion of Cooper’s ligament | | | | |
| Yes | 18 (30.000%) | 3 (37.500%) | 0.695 | 19 (29.231%) | 22 (59.459%) | 0.005 |
| No | 42 (70.000%) | 5 (62.500%) | 46 (70.769%) | 15 (40.541%) |
| BI-RADS | | | | |
| 3 | 2 (3.333%) | 0 (0.000%) | 0.803 | 0 (0.000%) | 0 (0.000%) | 0.126 |
| 4a | 9 (15.000%) | 2 (25.000%) | 9 (13.846%) | 2 (5.405%) |
| 4b | 17 (28.333%) | 1 (12.500%) | 18 (27.692%) | 5 (13.514%) |
| 4c | 13 (21.667%) | 2 (25.000%) | 14 (21.538%) | 9 (24.324%) |
| 5 | 19 (31.667%) | 3 (37.500%) | 24 (36.923%) | 21 (56.757%) |
The results showed that the molecular subtype of luminal B type (OR = 4.405, 95% CI was 1.194–20.368, P = 0.037), maximum lesion diameter of ≥5 cm (OR = 8.734, 95% CI was 2.156–38.796, P = 0.003), and tumor invasion of Cooper’s ligament (OR = 3.295, 95% CI 1.529–7.303, P = 0.004) were independent influence factors of heavy axillary lymph node tumor burden. Moreover, similar to the above analysis, neoadjuvant chemotherapy (OR = 6.951, 95% CI 2.133–25.144, P = 0.002 was also one of the risk factors. We conducted a literature review and data analysis and found that this is a false-positive result, which will be discussed in the discussion section (Table 7).

### TABLE 4 Differences of lymph node tumor burden of HER-2 overexpression type breast cancer regarding different ABVS features.

| ABVS features                   | Sentinel lymph node tumor burden | Axillary lymph node tumor burden |
|--------------------------------|----------------------------------|---------------------------------|
|                                | Mild (OR) | Heavy (OR) | P     | Mild (OR) | Heavy (OR) | P     |
| Tumor size                     |           |            |      |           |            |      |
| ≥5 cm                          | 1 (5.882%) | 0 (0.000%) | 0.389| 1 (5.000%) | 1 (25.000%) | 0.405|
| 2–5 cm                         | 11 (64.706%) | 0 (0.000%) |      | 15 (75.000%) | 3 (75.000%) |      |
| ≤2 cm                          | 5 (29.412%) | 1 (100.000%) |     | 4 (20.000%) | 0 (0.000%) |      |
| Orientation                    |           |            |      |           |            |      |
| Not parallel                   | 3 (17.647%) | 0 (0.000%) | 1.000| 5 (25.000%) | 3 (75.000%) | 0.091|
| Parallel                       | 14 (82.353%) | 1 (100.000%) |     | 15 (75.000%) | 1 (25.000%) |      |
| Shape                          |           |            |      |           |            |      |
| Regular                        | 1 (5.882%) | 0 (0.000%) | 1.000| 3 (15.000%) | 0 (0.000%) | 1.000|
| Irregular                      | 16 (94.118%) | 1 (100.000%) |     | 17 (85.000%) | 4 (100.000%) |      |
| Echo pattern                   |           |            |      |           |            |      |
| Hypoechoic                     | 15 (88.235%) | 1 (100.000%) | 1.000| 17 (85.000%) | 4 (100.000%) | 1.000|
| Mixed solid echo               | 2 (11.765%) | 0 (0.000%) |      | 3 (15.000%) | 0 (0.000%) |      |
| Margin                         |           |            |      |           |            |      |
| Circumscribed                  | 1 (5.882%) | 0 (0.000%) | 0.389| 0 (0.000%) | 0 (0.000%) | 0.135|
| Angular                        | 4 (23.529%) | 1 (100.000%) |     | 8 (40.000%) | 0 (0.000%) |      |
| Microlobulated                 | 1 (5.882%) | 0 (0.000%) |      | 4 (20.000%) | 0 (0.000%) |      |
| Spiculated                     | 11 (64.706%) | 0 (0.000%) |      | 8 (40.000%) | 4 (100.000%) |      |
| Posterior acoustic pattern     |           |            |      |           |            |      |
| Enhancement                    | 2 (11.765%) | 0 (0.000%) | 0.278| 7 (35.000%) | 1 (25.000%) | 0.032|
| Shadow                         | 2 (11.765%) | 1 (100.000%) |     | 3 (15.000%) | 3 (75.000%) |      |
| No change                      | 13 (76.471%) | 0 (0.000%) |      | 10 (50.000%) | 0 (0.000%) |      |
| Microcalcifications            |           |            |      |           |            |      |
| Present                        | 6 (35.294%) | 0 (0.000%) | 1.000| 10 (50.000%) | 0 (0.000%) | 0.114|
| Absent                         | 11 (64.706%) | 1 (100.000%) |     | 10 (50.000%) | 4 (100.000%) |      |
| Acoustic halo                  |           |            |      |           |            |      |
| Present                        | 2 (11.765%) | 0 (0.000%) | 1.000| 1 (5.000%) | 0 (0.000%) | 1.000|
| Absent                         | 15 (88.235%) | 1 (100.000%) |     | 19 (95.000%) | 4 (100.000%) |      |
| Retraction phenomenon          |           |            |      |           |            |      |
| Present                        | 0 (0.000%) | 0 (0.000%) | 1.000| 1 (5.000%) | 0 (0.000%) | 1.000|
| Absent                         | 17 (100.000%) | 1 (100.000%) |     | 19 (95.000%) | 4 (100.000%) |      |
| Invasion of Cooper’s ligament  |           |            |      |           |            |      |
| Yes                            | 2 (11.765%) | 0 (0.000%) | 1.000| 4 (20.000%) | 1 (25.000%) | 1.000|
| No                             | 15 (88.235%) | 1 (100.000%) |     | 16 (80.000%) | 3 (75.000%) |      |
| BI-RADS                         |           |            |      |           |            |      |
| 3                              | 1 (5.882%) | 0 (0.000%) | 0.645| 0 (0.000%) | 0 (0.000%) | 0.223|
| 4a                             | 4 (23.529%) | 0 (0.000%) |      | 0 (0.000%) | 0 (0.000%) |      |
| 4b                             | 6 (35.294%) | 1 (100.000%) |     | 9 (45.000%) | 0 (0.000%) |      |
| 4c                             | 0 (0.000%) | 0 (0.000%) |      | 2 (10.000%) | 1 (25.000%) |      |
| 5                              | 6 (35.294%) | 0 (0.000%) |      | 9 (45.000%) | 3 (75.000%) |      |
The accuracy of SLNB in the determination of axillary lymph node tumor burden

A total of 251 cases of breast lesions were included. One hundred forty-four cases underwent SLNB, 178 cases underwent ALND, and 71 cases underwent both operations. The 71 patients who underwent both SLNB and ALND were grouped according to the results of SLNB: 10 cases (14.085%) with heavy lymph node tumor burden and 61 cases (85.915%) with mild lymph node tumor burden. The results of SLNB were compared with the results of ALND, and the comparison showed a sensitivity of

| TABLE 5 Differences of lymph node tumor burden of triple-negative type breast cancer regarding different ABVS features. |
|---------------------------------------------------------------|
| **ABVS features**                          | **Sentinel lymph node tumor burden** | **Axillary lymph node tumor burden** |
|                                              | **Mild** | **Heavy** | **P** | **Mild** | **Heavy** | **P** |
| Tumor size                                    |          |          |      |          |          |      |
| ≥5 cm                                        | 0 (0.000%) | 0 (0.000%) | / | 1 (6.250%) | 1 (16.667%) | 0.424 |
| 2-5 cm                                       | 10 (62.500%) | 0 (0.000%) |     | 11 (68.750%) | 5 (83.333%) |
| ≤2 cm                                        | 6 (37.500%) | 0 (0.000%) |     | 4 (25.000%) | 0 (0.000%) |
| Orientation                                  |          |          |      |          |          |      |
| Not parallel                                 | 7 (43.750%) | 0 (0.000%) | / | 6 (37.500%) | 2 (33.333%) | 1.000 |
| Parallel                                     | 9 (56.250%) | 0 (0.000%) |     | 10 (62.500%) | 4 (66.667%) |
| Shape                                         |          |          |      |          |          |      |
| Regular                                      | 5 (31.250%) | 0 (0.000%) | / | 6 (37.500%) | 0 (0.000%) | 0.133 |
| Irregular                                    | 11 (68.750%) | 0 (0.000%) |     | 10 (62.500%) | 6 (100.000%) |
| Margin                                        |          |          |      |          |          |      |
| Circumscribed                                | 0 (0.000%) | 0 (0.000%) | / | 1 (6.250%) | 0 (0.000%) | 0.340 |
| Angular                                      | 7 (43.750%) | 0 (0.000%) |     | 7 (43.750%) | 3 (50.000%) |
| Microlobulated                               | 4 (25.000%) | 0 (0.000%) |     | 5 (31.250%) | 0 (0.000%) |
| Spiculated                                   | 5 (31.250%) | 0 (0.000%) |     | 3 (18.750%) | 3 (50.000%) |
| Echo pattern                                 |          |          |      |          |          |      |
| Hypoechoic                                   | 12 (75.000%) | 0 (0.000%) | / | 14 (87.500%) | 6 (100.000%) | 1.000 |
| Mixed solid echo                             | 4 (25.000%) | 0 (0.000%) |     | 2 (12.500%) | 0 (0.000%) |
| Posterior acoustic pattern                   |          |          |      |          |          |      |
| Enhancement                                  | 6 (37.500%) | 0 (0.000%) | / | 4 (25.000%) | 0 (0.000%) | 0.183 |
| Shadow                                       | 1 (6.250%) | 0 (0.000%) |     | 0 (0.000%) | 1 (16.667%) |
| No change                                    | 9 (56.250%) | 0 (0.000%) |     | 12 (75.000%) | 5 (83.333%) |
| Microcalcifications                          |          |          |      |          |          |      |
| Present                                      | 2 (12.500%) | 0 (0.000%) | / | 4 (25.000%) | 0 (0.000%) | 0.541 |
| Absent                                       | 14 (87.500%) | 0 (0.000%) |     | 12 (75.000%) | 6 (100.000%) |
| Acoustic halo                                |          |          |      |          |          |      |
| Present                                      | 3 (18.750%) | 0 (0.000%) | / | 4 (25.000%) | 1 (16.667%) | 1.000 |
| Absent                                       | 13 (81.250%) | 0 (0.000%) |     | 12 (75.000%) | 5 (83.333%) |
| Retraction phenomenon                        |          |          |      |          |          |      |
| Present                                      | 1 (6.250%) | 0 (0.000%) | / | 2 (12.500%) | 0 (0.000%) | 1.000 |
| Absent                                       | 15 (93.750%) | 0 (0.000%) |     | 14 (87.500%) | 6 (100.000%) |
| Invasion of Cooper’s ligament                |          |          |      |          |          |      |
| Yes                                          | 0 (0.000%) | 0 (0.000%) | / | 4 (25.000%) | 4 (66.667%) | 0.137 |
| No                                           | 16 (100.000%) | 0 (0.000%) |     | 12 (75.000%) | 2 (33.333%) |
| BI-RADS                                       |          |          |      |          |          |      |
| 3                                            | 1 (6.250%) | 0 (0.000%) | / | 0 (0.000%) | 0 (0.000%) | 0.004 |
| 4a                                           | 4 (25.000%) | 0 (0.000%) |     | 5 (31.250%) | 1 (16.667%) |
| 4b                                           | 9 (55.250%) | 0 (0.000%) |     | 7 (43.750%) | 1 (16.667%) |
| 4c                                           | 1 (6.250%) | 0 (0.000%) |     | 4 (25.000%) | 0 (0.000%) |
| 5                                            | 1 (6.250%) | 0 (0.000%) |     | 0 (0.000%) | 4 (66.667%) |
TABLE 5 Multivariate-logistic regression analysis of the clinical features and axillary lymph node tumor burden.

| Variable                        | OR (95% CI)   | P    |
|--------------------------------|---------------|------|
| Molecular subtype              |               |      |
| Luminal A                      | 1.666 (0.292-10.933) | 0.570|
| Luminal B                      | 7.766 (2.022-43.649)  | 0.008|
| Triple negative                | 3.288 (0.645-20.811)  | 0.169|
| HER-2                          | 1.000         |      |
| Ki-67                          |               |      |
| ≥20%                           | 1.705 (0.427-9.279)  | 0.483|
| <20%                           | 1.000         |      |
| Neoadjuvant chemotherapy       |               |      |
| Yes                            | 6.657 (2.017-24.57)  | 0.003|
| No                             | 1.000         |      |
| Nipple invasion                |               |      |
| Present                        | 14.147 (2.186-133.948) | 0.009|
| Absent                         | 1.000         |      |

57.143%, a specificity of 96.491%, and an accuracy of 88.732%. The graphed ROC curve is shown in Figure 1E, and the area under the ROC curve (AUC) is 0.768.

Nomogram for predicting the probability of heavy lymph node tumor burden

All of the patients who underwent ALND were included in the cohort. The cohort was divided into a training set and a validation cohort at a 1:1 ratio in chronological order. A total of 178 cases of lesions were included, with 89 cases in each of the training sets and the validation cohort. The breast cancer preoperative examination indicators with statistical significance in the multivariate logistic analysis were included as predictors to establish a nomogram scoring system. The predictors included tumor size, molecular classification, and Cooper’s ligament invasion. Among them, the molecular subtype of luminal B type was assigned a score of 25 points, and other molecular subtypes were assigned 0 points; the maximum lesion diameter of ≤2 cm was assigned 0 points, the maximum lesion diameter of 2–5 cm was assigned 50 points, and the maximum lesion diameter of ≥5 cm was assigned 100 points; the presence of Cooper’s ligament invasion was assigned 42.5 points, and its absence was assigned 0 points. The statistical model automatically generated all of the assigned scores (Figure 1A). The concordance index (C-index) of the nomogram scoring system for predicting the probability of heavy lymph node tumor burden on the training set is 0.743, the average absolute error is 0.05 (Figure 1B), and the area under the curve is 0.743 (Figure 1D). The validation cohort was used to calibrate the nomogram scoring system for predicting the probability of heavy lymph node tumor burden. The calibration curve is shown in Figure 1C with a consistency index of 0.711 and an average absolute error of 0.054. The results of the validation set and the training set are consistent. The best cutoff value of the ABVS nomogram is 81.146 points according to the ROC curve.

To confirm whether the ABVS nomogram can be a supplement to SLNB, we developed a new model based on ABVS features and SLNB. The results showed that the AUC and C-index are 0.889, and the average absolute error is 0.029. Meanwhile, the best cutoff value is 178.965 points according to the ROC curve (Figure 2).

Discussion

In this study, we showed the landscape of ABVS features in breast cancer, including the analyses in different clinical subgroups and molecular subtypes. Then, we successfully identified tumor size and invasion of Cooper’s ligament as the lymph node tumor burden-related ABVS features, combined with the molecular subtype; we developed a nomogram prediction model, which has a convincible AUC (0.743), while the AUC of SLNB is 0.768. Furthermore, when in combination with ABVS and SLNB, the AUC can increase to 0.889. Therefore, this model may be used for individual decision-making.

In breast cancer, the expression status of ER, PR, and HER-2 has important predictive values for prognosis. The recurrence rate of ER- or PR-positive breast cancer changes with time (24–26). In this study, compared with other molecular subtypes of breast cancer, the luminal B type was more closely associated with heavy axillary lymph node tumor burden. Previously, it has been reported that poorly differentiated breast tumors are mainly of the luminal B type (27), and breast tumors with positive axillary lymph nodes are often of the luminal B type (27, 28). Luminal B-type breast cancer is more likely to have a heavier axillary lymph node tumor burden. This result may be due to the interaction of several steroid receptors. The plasminogen activator inhibitor is one of the predictors of axillary lymph node metastasis, but it only functions in PR-positive tumors (29). The expression of vimentin and Ki-67 may indicate that the long-term prognosis of ER-positive tumors is poor (27), and studies have shown that vimentin is positively correlated with the expression of ER in breast cancer (30, 31). Although whether the expression of ER and PR can be used as a predictor of axillary lymph node status is still controversial (32), there are studies suggesting the correlation between the expression status of ER and lymph node involvement (33). The expression level of Ki-67 can be used to measure the level of cell proliferation. Ki-67 <14% is considered a low proliferation state, and ≥14% is considered a high proliferation state (34). At present, the cutoff level of Ki-67 is still controversial (35, 36). Some studies suggested that using...
TABLE 7  Multivariate-logistic regression analysis of the ABVS features and axillary lymph node tumor burden.

| Variable                      | OR (95% CI)       | P   |
|-------------------------------|-------------------|-----|
| Molecular subtype             |                   |     |
| Luminal A                     | 0.939 (0.153-5.851)| 0.945 |
| Luminal B                     | 4.405 (1.194-20.368)| 0.037 |
| Triple negative               | 2.028 (0.381-11.803)| 0.412 |
| HER-2                         | 1.000             |     |
| Neoadjuvant chemotherapy      |                   |     |
| Yes                           | 6.951 (2.133-25.144)| 0.002 |
| No                            | 1.000             |     |
| Tumor size                    |                   |     |
| ≥5 cm                         | 8.734 (2.156-38.796)| 0.003 |
| 2–5 cm                        | 1.491 (0.629-3.648)| 0.370 |
| ≤2 cm                         | 1.000             |     |
| Acoustic halo                 |                   |     |
| Present                       | 2.205 (0.910-5.358)| 0.078 |
| Absent                        | 1.000             |     |
| Invasion of Cooper’s ligament |                   |     |
| Yes                           | 3.295 (1.529-7.303)| 0.004 |
| No                            | 1.000             |     |
| Posterior acoustic pattern    |                   |     |
| Enhancement                   | 1.596 (0.440-5.237)| 0.319 |
| Shadow                        | 1.584 (0.634-3.910)| 0.451 |
| No change                     | 1.000             |     |

20% as the cutoff value for Ki-67 could better reflect the proliferation status of tumor cells (37). Therefore, in the logistic regression analysis of this study, 20% was used as the cutoff value of Ki-67. The difference between luminal A-type and luminal B-type breast cancers lies in the different expression levels of Ki-67. The luminal B-type breast cancer has a higher expression level of Ki-67 than the luminal A type, and then the proliferation of its tumor cells is more active.

A study has shown that tumor size is one of the predictors of axillary lymph node metastasis (38). Some scholars have identified a linear relationship between tumor size and axillary lymph node metastasis (39). There were 20 cases with a maximum lesion diameter of ≥5 cm in this study. In this group, the risk of heavy axillary lymph node tumor burden was eight times the risk in other groups, which is basically consistent with the results of a previous study (5). The Cooper’s ligament is a fiber bundle between the breast’s lobules that connects the deep and top layer of the superficial fascia and supports and secures the breast. When the lesion invades the Cooper’s ligament, the ultrasound manifests traction and thickening of the Cooper’s ligament. In this study, according to whether the Cooper’s ligament was invaded, all of the patients were divided into two groups. The results showed that the risk of heavy axillary lymph node tumor burden when the Cooper’s ligament was invaded was three times higher than that of the non-invaded group, which is consistent with previous studies (40, 41).

Neoadjuvant chemotherapy has a positive effect on prolonging the survival time of breast cancer patients; however, some studies have also shown that neoadjuvant chemotherapy cannot achieve the expected effect for all breast cancer patients (42). Neoadjuvant chemotherapy is not effective on lymph nodes, the efficacy of complete remission is only about 40%, and different molecular subtypes respond differently to neoadjuvant chemotherapy (23). Therefore, we included it in our multivariate analysis. The results showed that patients who received neoadjuvant chemotherapy had a higher lymph node tumor burden. The reason is that patients with late-stage cancer were included in neoadjuvant chemotherapy. At the same time, the effective rate of the treatment was low, and the response of lymph nodes was even lower, which led to false-positive results. Therefore, this result’s essential cause is that these patients were in an advanced stage and not because neoadjuvant chemotherapy aggravated lymph node metastasis.

Studies have suggested that pathological classification is one of the prognostic factors of breast cancer (43), but no significant statistical difference was found in this study. The possible reason may be that there is no linear correlation between the pathological classification and the malignant degree of breast cancer. The evaluation index of this study was lymph node tumor burden, i.e., classifying the degree of lymphatic metastasis instead of analyzing whether there is axillary lymph node metastasis in breast cancer, which may have caused indistinguishable pathological classification.

In the malignant and benign breast lesion differentiation, ABVS diagnostic performance is similar to that of handheld ultrasound (HHUS), based on the evidence available in the previous studies (8, 44, 45). However, a great advantage of ABVS in breast lesion characterization in comparison to HHUS is its capability of obtaining details on the reconstructed coronal plane’s morphological features (8). Therefore, it can be sensibly concluded that in terms of differential findings assisted by coronal reconstruction, ABVS might be better when compared to HHUS (8). In our analysis, the Cooper’s ligament has been confirmed to have a relation with lymph node tumor burden, owing to the sensibly and completely ability of ABVS. On the other hand, in the differentiation of breast lesions that are malignant and benign, the ABVS coronal plane retraction phenomenon is perceived as having high probability as a diagnostic feature. However, we have not found any reports exploring the relationship between retraction phenomenon and lymphatic metastasis of breast cancer. Our findings suggest that the retraction phenomenon may not be closely related to the lymphatic metastasis of breast cancer, and further verification is needed.

This study has limitations. This research is a retrospective study. All of the acoustic features of breast lesions were extracted from saved images. Although the saved images can be reconstructed by the workstation and viewed repeatedly, there are still possible information omissions or misjudgments. Some breast cancer lesions would not be identified well by sonography;
therefore, the ABVS model may not be suitable for all the breast cancer patients, and more studies focusing on these patients are needed. However, the ABVS and SLNB model may be the solution for these patients; further studies are needed.

In conclusion, by integrating the real-world data, we showed the landscape of ABVS features in the breast cancer, including the analyses in different clinical subgroups and molecular subtypes. Then, we successfully identified the
lymph node tumor burden-related ABVS features, combined with the molecular subtype, and we developed a nomogram prediction model, which may be used for individual decision-making in the diagnosis and treatment of breast cancer.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by the ethics committee of Third Xiangya Hospital of Central South University. The patients/participants provided their written informed consent to participate in this study.

Author contributions

FZ, CC, and JX designed the study. CC, FZ, and ML collected the data and performed the major analysis. JX supervised the study. CC and FZ analyzed and interpreted the data. CC and FZ
did the statistical analysis. CC and FZ drafted the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by Hunan Provincial Natural Science Foundation of China (No. 2019J40459) and the project of Health Commission of Hunan Province (No. B2019177).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin (2022) 72(1):7–33. doi: 10.3322/caac.21708
2. Giudiano AE, Ballman KV, McCull L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACSOSG Z0011 (Alliance) randomized clinical trial. JAMA (2017) 318(10):918–26. doi: 10.1001/jama.2017.11470
3. Petrusis S, Christidis P, Margioulou-Sarkou C, Liberi A, Avoulos I, Margioulou-Sarkou G, et al. Axillary lymph node dissection vs sentinel node biopsy for early-stage clinically node-negative breast cancer: A systematic review and meta-analysis. Arch gynecology obstetrics (2022) 5(5):1–14. doi: 10.1007/s00375-022-06458-8
4. Millen EC, Cavalcante FP, Zerwes F, Novita G, de Souza ABA, Reis JHP, et al. The attitudes of Brazilian breast surgeons on axillary management in early breast cancer 10 years after the ACSOSG Z0011 trial first publication. Ann Surg Oncol (2022) 29(22):1087–95. doi: 10.1007/s10434-021-10812-6
5. Li J-W, Tong Y-Y, Jiang Y-Z, Shui X-J, Shi Z-T, Chang C. Clinicopathologic and ultrasonic variables associated with a heavy axillary nodal tumor burden in invasive breast carcinoma. J Ultrasound Med (2019) 38(7):1747–55. doi: 10.1002/jum.14863
6. Tseng J, Alban BF, Siegel E, Chung A, Giudiano AE, Amerisi FF. Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACSOSG Z0011 trial. Breast (2021) 27(3):216–21. doi: 10.10111/obj14191
7. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: Results from the NSABP b-32 randomised phase III trial. Lancet Oncol (2007) 8(10):881–8. doi: 10.1016/S1470-224X(07)70278-4
8. Meng Z, Chen C, Zhu Y, Zhang S, Wei C, Hu B, et al. Diagnostic performance of the automated breast volume scanner: A systematic review of inter-rater Reliability/Agreement and meta-analysis of diagnostic accuracy for differentiating benign and malignant breast lesions. Eur Radiol (2015) 25(12):3638–47. doi: 10.1007/s00330-015-3759-3
9. Zheng F-Y, Lu Q, Huang B-J, Xia H-S, Yan L-X, Wang X, et al. Imaging features of automated breast volume scanner: Correlation with molecular subtypes of breast cancer. Eur J Radiol (2017) 86:267–75. doi: 10.1016/j.ejrad.2016.11.032
10. Taherian-Fard A, Sfirari S, Ragan MA. Breast cancer classification: Linking molecular mechanisms to disease prognosis. Brief Bioinform (2015) 16(3):461–74. doi: 10.1093/bib/bbu020
11. Maambo EC, Ifode OB. Molecular classification and prognostication of breast cancer. Pathol Case Rep (2009) 14(3):129–34. doi: 10.1007/978-3-8342-7809-8_11
12. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA (2006) 295(21):2492–502. doi: 10.1001/jama.295.21.2492
13. Benelaud CU, Lefall LD, Dewitty RL, Naab TJ, Merghebe HM, Makambi KH, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: Age-specific prevalence and survival. J Surg Res (2007) 143(1):109–18. doi: 10.1016/j.jss.2007.03.085
14. Chang RF, Hou YL, Huang CS, Chen JH, Chang JM, Moon WK. Automatic detection of microcalcifications in breast ultrasound. Med Phys (2013) 40(10):102901. doi: 10.1118/1.4821098
15. Pauludelli RR, Freitas-Junior R, de Lucena C, Moreira MA, de Moraes VA, Bernardes-Junior JR, et al. Sonobreast: Predicting individualized probabilities of malignancy in solid breast masses with echographic expression. Breast J (2011) 17(2):152–9. doi: 10.1111/j.1524-4741.2010.01046.x
16. Elverci E, Barça AN, Aktaş H, Ozyo K, Zengin B, Çavuşoğlu M, et al. Nonpalpable BI-RADS 4 breast lesions: Sonographic findings and pathology correlation. Diagn Interventional Radiol (2015) 21(3):189. doi: 10.1515/dir-2014.14103
17. Goldrichs A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes—dealing with the diversity of breast cancer: Highlights of the st. galen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol (2011) 22(8):1736–47. doi: 10.1093/annonc/mdr304
18. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of clinical Oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 28(16):2784–95. doi: 10.1200/JCO.2009.25.6529
19. Lombardi A, LaZzeroni R, Bersigotti I, Vitale V, Amanti C. The proper ki-67 cut-off in hormone responsive breast cancer: A monoinstitutional analysis with long-term follow-up. Breast Cancer (Dove Med Press) (2011) 3:213–7. doi: 10.2147/btc.503440
20. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies—improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol (2015) 26(8):1533–46. doi: 10.1093/annonc/mdv221
21. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Gelber RD, Piccart-Gebhart M, et al. American society of clinical Oncology/College of American pathologists clinical practice guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 28(16):2784–95. doi: 10.1200/JCO.2009.25.6529
22. Fehm T, Wallwiener D. [Axillary dissection vs. no axillary dissection in early breast cancer]. Strahlenther Onkol (2012) 188(12):1155–7. doi: 10.1007/s00393-012-2404-7
23. Glaser A, Sinn H-P, Garcia-Eterine C, Riedel F, Hug S, Schaelgen B, et al. Heterogeneous responses of axillary lymph node metastases to neoadjuvant chemotherapy are common and depend on breast cancer subtype. Ann Surg Oncol (2019) 26(13):4381–9. doi: 10.1007/s10434-019-07915-6

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.881761/full#supplementary-material
24. Elledge R, Allred D. Clinical aspects of estrogen and progesterone receptors. Dis Breast (2004) 3:602–17. doi: 10.1186/bcr777
25. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res (2004) 6(3):109–18. doi: 10.1186/bcr777
26. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol (1996) 14(10):2738–46. doi: 10.1200/JCO.1996.14.10.2738
27. Pracella D, Bonin S, Barbazza R, Sapino A, Castellano I, Sulfaro S, et al. Are breast cancer molecular classes predictive of survival in patients with long follow-up? Dis Markers (2013) 35(6):595–605. doi: 10.1155/2013/347073
28. Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol (2009) 16(10):2705–10. doi: 10.1245/s10434-009-0606-2
29. Lange CA, Richer JK, Shen T, Horwitz KB. Convergence of progesterone and epidermal growth factor signaling in breast cancer: potentiation of mitogen-activated protein kinase pathways. J Biol Chem (1998) 273(47):31308–16. doi: 10.1074/jbc.273.47.31308
30. Kusinska RU, Kordek R, Bednarek AK, Piekarski JH, Potemski P. Does vimentin help to delineate the so-called ‘Basal type breast cancer’? Exp Clin Cancer Res (2009) 28:118. doi: 10.1186/1756-9966-28-118
31. Heatley M, Whiteside C, Maxwell P, Toner P. Vimentin expression in benign and malignant breast epithelium. J Clin Pathol (1993) 46(5):441–5. doi: 10.1136/jcp.46.5.441
32. Patani NR, Dwok MV, Douek M. Predictors of axillary lymph node metastasis in breast cancer: A systematic review. Eur J Surg Oncol (2007) 33(4):409–19. doi: 10.1016/j.ejso.2006.09.013
33. Bartlett JMS, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol (2007) 25(28):4423–30. doi: 10.1200/JCO.2007.11.0973
34. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. K67 index, HER2 status, and prognosis of patients with luminal b breast cancer. J Natl Cancer Inst (2009) 101(10):736–50. doi: 10.1093/jnci/djp082
35. Wu Y-T, Li X, Lu L-J, Guo D, Leung S, Snider J, et al. Effect of neoadjuvant chemotherapy on the expression of hormone receptors and ki-67 in Chinese breast cancer patients: A retrospective study of 525 patients. J BioMed Res (2017) 32(3):191–7. doi: 10.7555/JBR.32.20170059
36. Moazed V, Safari E, Kalantari Khandani B, Nemati A, Roordar A, Ben Razavi SA. Prognostic significance of reduction in K67 index after neoadjuvant chemotherapy in patients with breast cancer in kerman between 2009 and 2014. Iran J Pathol (2018) 13(1):71–7. doi: 10.30699/JP1.13.1.71
37. Prat A, Cheang MCU, Martin M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol (2013) 31(2):203–9. doi: 10.1200/JCO.2012.43.4134
38. Reyal F, Rouzier R, Depont-Hazelt B, Bollet MA, Pierga J-F, Alran S, et al. The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One (2011) 6(5):e20297. doi: 10.1371/journal.pone.0020297
39. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,748 breast cancer cases. Cancer (1989) 63(1):181–7. doi: 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
40. Paulinelli RR, Fretias-Junior R, Moreira MAR, Moraes V, Bernardes-Junior JRM, Vidal C, et al. Risk of malignancy in solid breast nodules according to their sonographic features. J Ultrasound Med (2005) 24(5):635–41. doi: 10.7863/jum.2005.24.5.635
41. Wojcinski S, Soliman AA, Schmidt I, Makowski L, Degenhardt F, Hillemanns P. Sonographic features of triple-negative and non-Triple-Negative breast cancer. J Ultrasound Med (2012) 31(10):1531–41. doi: 10.7863/jum.2012.31.10.1531
42. Mazari FAK, Sharma N, Dodwell D, Horgan K. Human epidermal growth factor 2-positive breast cancer with mammographic microcalcification: Relationship to pathologic complete response after neoadjuvant chemotherapy. Radiology (2018) 288(2):366–74. doi: 10.1148/radiol.2018170960
43. Chen W, Wang C, Fu F, Yang B, Chen C, Sun Y. A model to predict the risk of lymph node metastasis in breast cancer based on clinicopathological characteristics. Cancer Manag Res (2020) 12:10439–47. doi: 10.2147/cmar.2020.527240
44. Girometti R, Zanoteli M, Londero V, Linda A, Lorenzon M, Zucan I. Automated breast volume scanner (ABVS) in assessing breast cancer size: A comparison with conventional ultrasound and magnetic resonance imaging. Eur Radiol (2018) 28(3):1000–8. doi: 10.1007/s00330-017-5074-7
45. Schmachtenberg C, Fischer T, Hamon B, Rick U. Diagnostic performance of automated breast volume scanning (ABVS) compared to handheld ultrasonography with breast MRI as the gold standard. Acad Radiol (2017) 24(8):954–61. doi: 10.1016/j.acra.2017.01.021